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Abstract
Although SHIP is a well-established suppressor of IgE plus Ag-induced degranulation and 
cytokine production in bone marrow-derived mast cells (BMMCs), little is known about its role in 
connective tissue (CTMCs) or mucosal (MMCs) mast cells. In this study, we compared SHIP’s 
role in the development as well as the IgE plus Ag and TLR-induced activation of CTMCs, 
MMCs, and BMMCs and found that SHIP delays the maturation of all three mast cell subsets and, 
surprisingly, that it is a positive regulator of IgE-induced BMMC survival. We also found that 
SHIP represses IgE plus Ag-induced degranulation of all three mast cell subsets and that TLR 
agonists do not trigger their degranulation, whether SHIP is present or not, nor do they enhance 
IgE plus Ag-induced degranulation. In terms of cytokine production, we found that in MMCs and 
BMMCs, which are poor producers of TLR-induced cytokines, SHIP is a potent negative regulator 
of IgE plus Ag-induced IL-6 and TNF-α production. Surprisingly, however, in splenic or 
peritoneal derived CTMCs, which are poor producers of IgE plus Ag-induced cytokines, SHIP is a 
potent positive regulator of TLR-induced cytokine production. Lastly, cell signaling and cytokine 
production studies with and without LY294002, wortmannin, and PI3Kα inhibitor-2, as well as 
with PI3K p85α−/− BMMCs and CTMCs, are consistent with SHIP positively regulating TLR-
induced cytokine production via an adaptor-mediated pathway while negatively regulating IgE 
plus Ag-induced cytokine production by repressing the PI3K pathway.
Mast cells (MCs), which play critical roles in both allergic inflammation and host defense 
against microbial infections, can be subclassified based on distribution and granule contents 
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in mice into long-lived connective tissue MCs (CTMCs) and short-lived mucosal MCs 
(MMCs) (1, 2). In terms of distribution, CTMCs are located in sterile tissues such as the 
connective tissues of the skin and peritoneum as well as the submucosa of the 
gastrointestinal tract and the lung, whereas MMCs are present in nonsterile tissues, such as 
the mucosal linings of the gastrointestinal tract and the lungs. In terms of granule contents, 
CTMC granules contain serotonin and the proteoglycan, heparin (which is stained by 
safranin), whereas MMCs do not contain serotonin and possess the proteoglycan, chondrotin 
sulfate E, instead of heparin, and so do not stain with safranin (1, 3). As well, CTMC 
granules contain higher levels of histamine and different proteases than that present in MMC 
granules. Because it is difficult to get sufficient numbers of these CTMCs and MMCs for 
biochemical studies, most of what we know about MCs comes from experiments with in 
vitro derived bone marrow MCs (BMMCs), which are typically generated by culturing 
mouse bone marrow (BM) with IL-3. This culturing regimen results, after 4–6 wk, in a large 
number of uniform mature MCs, as assessed by the cell surface expression of FcεRI and c-
kit. These cells stain with alcian blue, but not with safranin, and are thought to resemble 
immature MMCs (4, 5). Interestingly, though, not only does there appear to be considerable 
plasticity between CTMCs and MMCs (6, 7), but introduction of BMMCs into MC-deficient 
mice results in the generation of both CTMCs and MMCs, depending on the tissues where 
these BMMCs lodge (7, 8).
MCs play a central role in type I hypersensitivity reactions, which occur following 
multivalent allergen-induced cross-linking of MC-bound IgE, and this mechanism of MC 
activation has been the focus of MC research for many years. A great deal has been learned 
about the intracellular signaling pathways involved (6, 9–11). However, because MCs are 
located at the portals between self and nonself and because of the more recent discovery that 
they express pathogen recognition receptors, like TLRs, they are now thought to be one of 
the first cells to recognize invading micro-organisms and trigger an appropriate immune 
response. In keeping with this, MC-deficient mice have been shown to be far more 
susceptible to septic peritonitis and other bacterial infections than their MC-reconstituted 
counterparts or wild-type (WT) mice (12, 13).
SHIP (also known as SHIP1) is well known for its role as a master negative regulator of 
FcεR1-mediated BMMC activation (14, 15). This is attributed to SHIP’s ability to hydrolyze 
the 5′-phosphate of the PI3K-generated second messenger phosphatidylinositol-3,4,5-
trisphosphate, making SHIP a negative regulator of the PI3K pathway. However, very little 
is known about its role in CTMCs or MMCs. We therefore compared SHIP’s role in the 
maturation, proliferation, and survival of CTMCs, MMCs, and BMMCs, as well as in IgE 
plus Ag-induced and TLR-induced activation of these MC subsets, and that is the focus of 
this study. Our findings are consistent with SHIP’s established role as a negative regulator of 
the PI3K pathway. In addition to that, however, our results using PI3K inhibitors and 
p85α−/− MCs also suggest that SHIP’s reported adaptor function(s) may be responsible for 
SHIP being a positive regulator of TLR-induced cytokine production.
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All cytokines and tissue culture media were purchased from StemCell Technologies 
(Vancouver, BC, Canada). LY294002 (LY) and wortmannin (W) were from Calbiochem 
(San Diego, CA), whereas the PI3Kα inhibitor-2 was from Cayman Chemical (Ann Arbor, 
MI). LPS serotype O127:B8 was from Sigma-Aldrich (St. Louis, MO). CpG, with the 
sequence 5′-TCCATGACGTTCCT-GACGTT-3′, was synthesized and HPLC purified by 
Invitrogen (Burlington, ON, Canada). The dsRNA used was a synthetic analog of 
polyinosine:cytosine from Sigma-Aldrich. Peptidoglycan (PGN) from Staphylococcus 
aureus was from Fluka (Buchs, Switzerland). IgE (anti-DNP, clone SPE-7) and DNP30–40-
human serum albumin (HSA) were from Sigma-Aldrich.
Mice
SHIP+/+ and SHIP−/− F2 mice, on a mixed C57BL/6 × 129Sv background, and p85α+/+ and 
p85α−/− C57BL/6 mice were used between 6 and 12 wk of age and housed in the Animal 
Resource Centre of the British Columbia Cancer Research Centre under specific pathogen-
free conditions and according to approved and ethical treatment of animal standards of the 
University of British Columbia. Animals were euthanized by CO2 as-phyxiation.
Generation of different MC subsets
BMMCs were generated, as described previously (16). To generate MMCs, mouse spleens 
were cut into small pieces and pressed through a 100-μm nylon cell strainer, and the 
resulting single-cell suspension was set up at 1 × 106 cells/ml in MMC medium (IMDM, 
10% FCS, 10 ng/ml IL-3). After 7 d, nonadherent cells were kept between 3 × 105 and 1 × 
106 cells/ml in MMC medium. To generate CTMCs, spleen cells were cultured at 1 × 106 
cells/ml in CTMC medium (IMDM, 10% FCS, 50 ng/ml stem cell factor [SCF]) and, after 7 
d, nonadherent cells were kept between 3 × 105 and 1 × 106 cells/ml in CTMC medium. 
Alternatively, IMDM was injected into the peritoneal cavity, and 1 × 106 nucleated cells/ml 
were plated in Opti-MEM I (Invitrogen), 10% FCS, 100 IU/ml penicillin, 100 μg/ml 
streptomycin, and 4% conditioned medium from murine SCF-secreting Chinese hamster 
ovary cells (CHO-KL). After 24 h, nonadherent cells were discarded, and fresh culture 
medium was added to the adherent cells. After 3 d, nonadherent and adherent cells, detached 
with trypsin-EDTA, were resuspended at 3 × 105 cells/ml in fresh culture medium. This was 
repeated twice per week. The resulting peritoneal CTMCs (pCTMCs) were used for 
experiments at 3–9 wk of culture (17). BM-derived connective tissue-like MCs (CT-like 
BMMCs) were also derived, in a fashion similar to BMMCs (16), but with the addition of 25 
ng/ml SCF plus 1 ng/ml IL-4 (18).
MC survival assay
For MC survival studies, MCs were washed, resuspended at 1.5 × 106 cells/ml in IMDM 
plus 0.1% BSA ± 10 μg/ml SPE-7 IgE, and 100 μl cells were seeded in a 96-well plate. 
Viable cell counts were determined by trypan blue exclusion.
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Degranulation assays were carried out, as previously described (18), in Tyrode’s buffer at 
6.25 × 106 cells/ml. Cells were seeded at 10 μl/well in 96-well V-bottom plates, and 
degranulation was triggered with 10 μl 2× concentrated stimulus, prepared in Tyrode’s 
buffer. After 1 h at 37°C, cells were centrifuged for 5 min at 335 × g and 10 μl cell-free 
supernatant, and the 0.5% Triton X-100 lysed cell pellet was analyzed for β-hexosaminidase 
levels (19). Percentage of degranulation was calculated by dividing the absorbance of the 
supernatant by the sum of the absorbencies of the supernatant and cell lysate.
Stimulation of MCs for cytokine production
To stimulate with TLR agonists ± IgE, MCs were incubated in MC starvation medium 
(IMDM, 10% FCS) at 1 × 106 cells/ml for 18 h (for BMMCs and MMCs) or 3 h (CTMCs 
and pCTMCs) at 37°C and then washed and resuspended in MC starvation medium at 1 × 
106 cells/ml. The cells (750 μl) were then seeded in 12-well flat-bottom plates. A total of 
750 μl MC starvation medium ± IgE (for nonstimulated [N/S] samples) or TLR ligands ± 
SPE-7 IgE, in MC starvation medium at twice the indicated final concentration, was added 
to the MCs for 24 h at 37°C. To stimulate with TLR ligands plus IgE plus Ag, MCs were 
washed and incubated at 1 × 106 cells/ml in MC starvation medium plus 0.1 μg/ml SPE-7 
for 18 h (for BMMCs and MMCs) or 3 h (CTMCs and pCTMCs) at 37°C. MCs were then 
washed and resuspended at 1 × 106 cells/ml with MC starvation medium plus 2 ng/ml DNP-
HSA, and 750 μl cells were seeded in 12-well flat-bottom plates. TLR ligands were made up 
in MC starvation medium at twice the indicated final concentration, and 750 μl was added to 
the MCs. For N/S samples, 750 μl MC starvation medium was added. For samples 
containing PI3K inhibitors, it was important to keep the final DMSO concentration ≤0.05% 
because of differential effects of higher DMSO concentrations on SHIP+/+ and SHIP−/− 
MCs. MCs were stimulated for 24 h at 37°C. Tissue culture supernatants were assayed for 
the concentration of IL-12p40, IL-6, IL-10, TNF-α, IFN-γ, and IL-4 by ELISA, according to 
the manufacturer’s instructions (BD Biosciences, Mississauga, ON, Canada).
Stimulation of MCs for SDS-PAGE and Western analysis
CTMCs, starved for 3 h, and MMCs, or BMMCs starved overnight, at 37°C in IMDM plus 
10% FCS were washed, resuspended in IMDM, and pre-treated or not for 20 min at 37°C 
with LY, W, or PI3K p110α inhibitor 2. The cells were then treated with LPS, IL-3, or IgE 
plus Ag for the indicated times, lysed with SDS sample buffer, boiled for 2 min, and loaded 
onto 10% polyacrylamide gels, as described previously (20). The following Abs were used 
for Western blotting: anti–phospho-IKKα/β (Ser176/180, catalog 2697), anti–phospho-p38 
MAPK (Thr180/Tyr182, catalog 9211), anti–phospho-JNK (Thr183/Tyr185, catalog 9251), and 
anti–phospho-ERK1/2 (Thr202/Tyr204, catalog 9106) all from Cell Signaling Technology 
(Pickering, ON, Canada); anti–phospho-Akt (S473, catalog 44-621G) from Invitrogen 
(Burlington, ON, Canada); and anti–Grb-2 (catalog sc-255) from Santa Cruz Biotechnology 
(Santa Cruz, CA).
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To assess maturity, MCs at 1 × 106 cells/ml in HBSS-modified medium containing 2% FCS 
(HF) were incubated for 30 min at 4°C with anti-CD16/32 (2.4G2) (StemCell Technologies) 
to block FcRs, and then incubated for 45 min in the dark with FcεR1α-FITC and c-kit 
allophycocyanin Abs, added at 1:1000 and 1:200, respectively. Then they were washed with 
HF and subjected to FACS at 5 × 105 cells/ml. To assess TLR4 and CD14 levels, 
unconjugated Abs to TLR4 (Santa Cruz Bio-technology, Santa Cruz, CA) and CD14 
(Pharmingen, Mississauga, ON, Canada) were used in conjunction with anti-rat PE 
secondary Ab. Data were collected using a FACSCalibur flow cytometer using CellQuest 
Pro software, and data were analyzed using FlowJo software.
Cytospin and granule staining of MCs
MCs (5 × 104 cells) in 0.5 ml PBS were centrifuged onto a microscope slide at 500 rpm for 
5 min in a Cytospin 3 centrifuge and stained for 15 min in 0.5% alcian blue/0.3% acetic acid 
solution, followed by 20 min in 0.1% safranin/0.1% acetic acid. Cells were air dried, and 
pictures were taken using an Axioplan 2 imaging microscope.
Analysis of TLR expression by RT-PCR
Total RNAwas prepared from MCs with TRIzol reagent, and genomic DNA contaminants 
were removed using the TURBO DNA-free kit (Ambion), according to each supplier’s 
recommendations. To RNA samples obtained from CTMCs, heparinase 1 (Sigma-Aldrich) 
was added according to the supplier’s recommendations. First-strand synthesis was 
performed using Moloney murine leukemia virus reverse transcription. The reactions were 
performed as per the manufacturer’s instructions, except the reactions were linearly upscaled 
to 25 μl. An oligo(dT)18 primer was used. PCRs were performed using the Phusion High-
Fidelity DNA Polymerase kit. Reactions were performed in a 25 μl total volume consisting 
of 1 μl template, 16.5 μl PCR-H2O, 5 μl 5× Phusion HF buffer (containing 7.5 mM MgCl2), 
0.75 μl DMSO, 0.25 μl Phusion High-Fidelity DNA Polymerase (2 U/μl), 0.5 μl 10 μM 
forward primer solution, 0.5 μl 10 μM reverse primer solution, and 0.5 μl dNTP (10 mM 
each) solution. PCRs with specific primers for GAPDH were carried out with an annealing 
temperature of 63°C and with the oligonucleotide primers 5′-TTAGCCCCCC-
TGGCCAAGG-3′ and 5′-CTTACTCCTTGGAGGCCATG-3′, amplifying a 541-bp 
fragment. PCRs for mouse TLRs were performed with primers from Invivogen (version 
07H09-SV) and carried out with an annealing temperature of 58°C. PCR amplifications 
were performed at 98°C for 75 s (initial denaturing step), followed by 35 cycles at 98°C for 
15 s, 58°C or 63°C for 20 s, and 72°C for 30 s, followed by a final step at 72°C for 10 min. 
All reactions were run in a GeneAmp PCR System 9700 thermo cycler.
Results
SHIP is a negative regulator of MC maturation
To compare SHIP’s role in the maturation and proliferation of CTMCs and MMCs, SHIP+/+ 
and SHIP−/− mouse spleens were cultured in CTMC medium (containing SCF) or MMC 
medium (containing IL-3), respectively, as described previously (21). SHIP+/+ and SHIP−/− 
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BM cultures were also initiated for comparison (16). As shown in Fig. 1A, SHIP−/− MCs 
matured faster than WT MCs, as assessed by cell surface expression of c-kit and FcεR1α, 
regardless of the subtype examined, and this was most pronounced with CTMCs and 
BMMCs. Whereas the SHIP−/− MMC maturation rate was only slightly faster than WT 
MMCs, it was consistently observed in five independent experiments. Of note, both SHIP+/+ 
and SHIP−/− CTMCs matured faster than MMCs or BMMCs, with >80% of SHIP+/+ and 
>95% of SHIP−/− spleen-derived cells becoming mature CTMCs by 3 wk of culture. By 
week 5, >90% of the cells in all cultures were mature MCs. Also of note, mature CTMCs 
were substantially smaller than MMCs or BMMCs, as assessed by flow cytometry, and the 
absence of SHIP resulted in slightly larger MMCs and BMMCs (Supplemental Fig. 1A).
Interestingly, SHIP’s influence on cell proliferation depended on the MC subtype (Fig. 1B). 
Whereas SHIP−/− CTMCs proliferated substantially faster than WT CTMCs, there was no 
significant difference in the growth of SHIP+/+ and SHIP−/− MMCs, and SHIP−/− BMMCs 
actually proliferated far slower than WT BMMCs. Of note, staining of the different SHIP+/+ 
and SHIP−/− mature MC subtypes with safranin, which stains heparin red (1, 3), and with 
alcian blue, which stains chondroitin sulfate blue (1, 3), confirmed that the derived CTMCs 
were indeed CTMCs, that the MMCs and BMMCs were mucosal-like MCs. These staining 
studies also showed that the absence of SHIP did not prevent the appearance of these 
granular components (Supplemental Fig. 1B). We also compared the cell surface expression 
of c-kit and FcεR1α on week 5 cultures of SHIP+/+ and SHIP−/− CTMCs, MMCs, and 
BMMCs by flow cytometry and found they all expressed similar levels of these two 
maturation markers (Supplemental Fig. 1C).
SHIP enhances IgE-induced BMMC survival
Because IgE, in the absence of Ag, has been shown to enhance BMMC survival [with some 
IgEs, e.g., SPE-7, being much more potent (cytokinergic) than others (22–24)], we asked 
whether IgE was also capable of enhancing the survival of MMCs and CTMCs when 
deprived of their growth factors. As shown in the left panel of Fig. 1C, IgE substantially 
enhanced the survival of CTMCs, with no difference being observed between SHIP+/+ and 
SHIP−/− MCs. The survival of SHIP+/+ and SHIP−/− MMCs, however, was only slightly 
increased with IgE (middle panel, Fig. 1C), although this was mainly because MMCs were 
substantially more capable of surviving in the absence of IgE than CTMCs. Once again, the 
presence of SHIP made no difference to survival, with or without IgE. Lastly, as shown in 
the right panel of Fig. 1C, SHIP+/+ and SHIP−/− BMMCs survived equally well, and the best 
of the three MC subtypes, in the absence of IgE. Interestingly, however, whereas IgE 
increased the survival of both SHIP+/+ and SHIP−/− BMMCs over the 4 d of the study, it was 
far more effective at promoting the proliferation/survival of SHIP+/+ BMMCs. Thus, 
surprisingly, SHIP appears to be a positive regulator of BMMC proliferation/survival in the 
presence of a highly cytokinergic IgE.
SHIP is a negative regulator of CTMC, MMC, and BMMC degranulation
To explore SHIP’s role following the activation of mature CTMCs and MMCs, we first 
asked whether SHIP, which is an established negative regulator of IgE plus Ag-induced 
BMMC degranulation (18), also negatively regulated CTMC and MMC degranulation. 
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Specifically, we compared the ability of SHIP+/+ and SHIP−/− CTMCs, MMCs, and 
BMMCs to degranulate in response to IgE plus Ag by preloading the MCs with 0.1 μg/ml 
SPE-7 IgE and then stimulating with increasing concentrations of DNP-HSA. As shown in 
Fig. 2A, all subsets of SHIP−/− MCs degranulated significantly more than SHIP+/+ MCs at 
all Ag concentrations tested, establishing that SHIP negatively regulates IgE plus Ag-
induced MMC and CTMC degranulation. However, the SHIP−/− BMMCs and MMCs were 
more sensitive to IgE plus Ag-induced degranulation than SHIP−/− CTMCs because they 
degranulated to a significant extent with as little as 1 ng/ml Ag.
TLR agonists neither trigger nor synergize with IgE plus Ag in triggering SHIP+/+ or SHIP−/− 
CTMC, MMC, or BMMC degranulation
Because MCs are among the first cells to recognize invading microorganisms, and they do 
so, in large part, via their TLRs, we asked whether TLR agonists triggered degranulation of 
any of the three MC subsets and, if so, whether SHIP influenced the extent of degranulation. 
Specifically, SHIP+/+ and SHIP−/− MMCs, CTMCs, and BMMCs were stimulated with 
concentrations of TLR agonists that gave maximal cytokine production from BMMCs in 
preliminary studies, that is, 100 ng/ml Escherichia coli LPS, 50 μg/ml dsRNA, 0.3 μM 
phosphorothioate-modified CpG-containing oligodeoxynucleotide (CpG), and 10 μg/ml 
PGN. However, there was no degranulation in any MC subset with these TLR agonists 
whether SHIP was present or not (Fig. 2B). This is consistent with other reports showing 
TLR agonists do not induce BMMC degranulation (25, 26), with the exception of PGN, 
which has been reported to induce BMMC degranulation under certain circumstances (27).
Because synergistic interactions between TLR agonists and IgE plus Ag have been reported 
for cytokine production from BMMCs (26, 28, 29), we next asked whether the same TLR 
agonists could augment IgE plus Ag-induced degranulation, that is, SHIP+/+ or SHIP−/− 
MMCs, CTMCs, and BMMCs were preloaded with 0.1 μg/ml SPE-7 IgE and then 
stimulated with 2 ng/ml Ag in the presence or absence of TLR ligands for 1 h. As shown in 
Fig. 2C, none of the TLR agonists increased degranulation. These studies were repeated 
with the SHIP−/− MMCs and BMMCs at a lower Ag concentration (0.2 ng/ml) because these 
cells maximally degranulated with 2 ng/ml Ag. However, the addition of TLR ligands once 
again did not increase degranulation (Fig. 2D), confirming that TLR stimulation did not 
affect IgE plus Ag-induced degranulation.
Because we showed in previous studies that SHIP−/− BMMCs, unlike WT BMMCs, 
degranulated in the presence of SCF (30) or following addition of highly cytokinergic IgEs 
[without subsequent Ag-induced cross-linking (18)], we asked whether this held true for 
SHIP−/− MMCs and CTMCs as well. As shown in Fig. 2E, SHIP−/− MMCs did indeed 
degranulate to some extent in the presence of SPE-7 IgE or with SCF, but SHIP−/− CTMCs 
did not, perhaps reflecting their lower responsiveness to IgE plus Ag-induced degranulation.
SHIP positively regulates TLR-induced, but negatively regulates IgE plus Ag-induced 
cytokine production from MCs
Activated MCs not only degranulate, releasing preformed mediators of inflammation, but 
also secrete de novo synthesized mediators, and this release can occur in the absence of 
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degranulation (31, 32). Because TLR stimulation has been shown to be a major trigger of 
this de novo mediator release from BMMCs (13, 33), we compared the ability of SHIP+/+ 
and SHIP−/− CTMCs, MMCs, and BMMCs to secrete the cytokines IL-6, TNF-α, IL-12, and 
IL-10 in response to dsRNA, which binds TLR3 and acts through a MyD88-independent 
pathway; CpG, which binds TLR9 and signals via the MyD88-dependent pathway; and LPS, 
which binds TLR4 and stimulates both MyD88-dependent and independent pathways (34). 
As shown in Fig. 3, when stimulated with TLR agonists alone, WT CTMCs were by far the 
most robust producers of IL-6, TNF-α, IL-12, and IL-10. In marked contrast, SHIP−/− 
CTMCs produced little or no cytokines in response to these TLR agonists. These results 
suggest, quite surprisingly, that SHIP is a potent positive regulator of TLR-induced cytokine 
production from CTMCs. Both SHIP+/+ and SHIP−/− MMCs, in contrast, produced little to 
no cytokines in response to TLR stimulation. Lastly, BMMCs, like MMCs, were poor 
responders, but WT BMMCs were slightly better than their SHIP−/− counterparts at 
producing IL-6, again suggesting SHIP is a positive regulator of TLR-induced cytokine 
production, but that MMCs and BMMCs are far less responsive to TLR ligands than 
CTMCs. Consistent with this, TNF-α, IL-12, and IL-10 were not detectable from TLR-
stimulated SHIP+/+ or SHIP−/− MMCs or BMMCs.
When MCs were stimulated for 24 h with TLR ligands in the presence of 0.1 μg/ml SPE-7 
IgE, there was no change in the level of cytokine production from either SHIP+/+ or SHIP−/− 
CTMCs (compare the top panels of Fig. 4 with those of Fig. 3). Also, IgE alone (the N/S 
columns) was incapable of stimulating cytokine secretion from WT or SHIP−/− CTMCs. 
Interestingly, however, SHIP−/− MMCs and SHIP−/− BMMCs now produced higher levels 
of IL-6 and TNF-α than their WT counterparts (compare middle and bottom panels of Fig. 4 
with those of Fig. 3), and IgE alone triggered a substantial amount of IL-6 and TNF-α from 
SHIP−/− MMCs and BMMCs. However, IgE plus TLR ligands, like TLR ligands alone, 
were incapable of triggering the secretion of detectable levels of IL-12 or IL-10 from these 
cells. These results suggest that SHIP is a negative regulator of IgE-induced cytokine 
secretion from MMCs and BMMCs, consistent with our previous studies showing that IgE 
stimulates more IL-6 from SHIP−/− than from WT BMMCs (35).
When the different MC subsets were stimulated with TLR agonists in the presence of IgE 
plus Ag, there was a slight increase in cytokine production from WT CTMCs, but still no 
detectable production of cytokines from SHIP−/− CTMCs (top panels of Fig. 5). 
Interestingly, of the TLR ligands tested, only CpG was capable of triggering detectable 
levels of the anti-inflammatory cytokine, IL-10, from WT CTMCs, and IgE ±Ag had no 
effect on this level (compare Figs. 3–5). Importantly, there was a dramatic increase in the 
levels of IL-6 and TNF-α produced by SHIP−/− MMCs and BMMCs, even without TLR 
ligand stimulation (N/S indicates IgE plus Ag without TLR stimulation in Fig. 5), and the 
levels increased with the addition of TLR agonists. However, IgE plus Ag ± TLR ligands 
stimulated far less IL-6 and TNF-α from WT MMCs and WT BMMCs, consistent with 
SHIP being a potent negative regulator of IgE plus Ag-induced cytokine production. 
Interestingly, however, the absence of SHIP did not increase IL-10 or IL-12 secretion to 
detectable levels.
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To confirm the unexpected finding that SHIP was a potent positive regulator of TLR-
induced cytokines from CTMCs, we also derived CTMCs from SHIP+/+ and SHIP−/− 
peritoneal cavity cells (pCTMCs), according to Malbec et al. (17), and found, as shown in 
Fig. 6A, that LPS once again triggered far more IL-6 and TNF-α from these SHIP+/+ than 
SHIP−/− CTMCs.
SHIP influences TLR expression in MCs
To gain some insight into why TLR-stimulated WT CTMCs secreted far higher cytokine 
levels than either SHIP−/− CTMCs or SHIP+/+ and SHIP−/− MMCs or BMMCs, we first 
examined the expression levels of their TLRs. RT-PCR analysis of the SHIP+/+ and SHIP−/− 
CTMCs, MMCs, and BMMCs revealed that the levels of TLR3 and TLR9 in SHIP−/− 
CTMCs were actually higher than in their WT counterparts, whereas TLR4 levels were 
about the same in the presence or absence of SHIP (Fig. 6B). Because we found TLR2 
expression was also far higher in SHIP−/− than SHIP+/+ CTMCs (Fig. 6B, top left panel), we 
compared cytokine production following PGN (a TLR2 agonist) stimulation of these cells 
and found that, even though WT CTMCs expressed far lower TLR2 levels, they secreted 
substantially higher levels of IL-6, TNF-α, IL-12, and IL-10 (Fig. 6C). Thus, because the 
SHIP+/+ CTMCs produced substantially higher levels of IL-6, TNF-α, IL-12, and IL-10, 
rather than lower levels, when TLR2, 3, 4, and 9 were stimulated, it was unlikely that this 
could be explained by differences in TLR expression. In contrast, the undetectable levels of 
TLR3 and TLR9 observed with SHIP+/+ and SHIP−/− MMCs and BMMCs were consistent 
with the relatively low response levels of these cells to dsRNA and CpG, respectively. The 
similar TLR expression pattern seen with MMCs and BMMCs reinforces the notion that 
these two MC subsets are closely related.
Because mRNA levels do not necessarily reflect protein levels and certainly not cell surface 
protein levels, we then assessed the cell surface levels of TLR4 and its coreceptor, CD14, on 
the different MC subsets. As shown in Supplemental Fig. 2, the levels were similar on all 
MC subsets. Thus, the different responses of the MC subsets to LPS were not due to 
different cell surface receptor levels.
IgE plus Ag or LPS stimulation of SHIP−/− MCs triggers higher PI3K pathway activity than 
in WT MCs
To gain some insight into why SHIP was a positive regulator of TLR-induced cytokine 
secretion but a negative regulator of IgE plus Ag-induced cytokine secretion, we carried out 
signaling studies with SHIP+/+ and SHIP−/− BMMCs. This was done not only because it was 
extremely difficult to obtain reproducible cell signaling results with CTMCs, but also to 
ensure that the same signaling pathways were available (i.e., same cellular context) to 
respond to LPS (which, as shown in the bottom panel of Fig. 3, triggers more IL-6 from WT 
BMMCs) and to IgE plus Ag (which, as shown in the N/S lanes of the bottom panel of Fig. 
5, triggers more IL-6 from SHIP−/− BMMCs). As shown in Fig. 7A, activation of the PI3K 
pathway (i.e., phosphorylation of Akt) by either IgE plus Ag (left panel) or by LPS (right 
panel) was consistently higher in SHIP−/− than WT BMMCs. This suggested that the PI3K 
pathway was a positive regulator of IgE plus Ag-induced cytokines, consistent with earlier 
studies with BMMCs (11, 30, 36), and perhaps a negative regulator of TLR-induced 
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cytokine secretion. Because the JNK and p38 pathways have been implicated in previous 
MC studies involving TLR-induced cytokines (26, 37, 38), we examined the activation of 
these pathways as well. Interestingly, whereas the phosphorylation of p38 may have been 
slightly more prolonged in SHIP−/− BMMCs (Fig. 7A), we were unable to detect any 
phospho-JNK in response to IgE plus Ag or LPS stimulation (data not shown). An 
examination of the phosphorylation of the third MAPK, ERK, suggested no difference with 
or without SHIP in response to IgE plus Ag, but perhaps more prolonged phosphorylation in 
the absence of SHIP following LPS stimulation (Fig. 7A). Because the NF-κB pathway has 
also been shown to play an important positive role in cytokine production from MCs (35), 
we also assessed the activation of its upstream activator, IKK, and found a similar IgE plus 
Ag-induced phosphorylation/activation of this Iκ kinase in the presence and absence of 
SHIP (Fig. 7A), but could not detect its phosphorylation in response to LPS (data not 
shown).
Reducing PI3K activity markedly reduces IgE plus Ag-induced, but does not increase LPS-
induced cytokine production from MCs
Given that SHIP is a negative regulator of the PI3K pathway (39), our results to this point 
suggested that the PI3K pathway was a positive regulator of IgE plus Ag-induced, but a 
negative regulator of TLR-induced cytokine production from MCs. However, because SHIP 
can also act as an adaptor (40–43), we wanted to rule in or out SHIP adaptor effects on 
cytokine production. To test this, we first used the PI3K inhibitors LY and W and PI3Kα 
inhibitor-2 (because preliminary studies with different p110 isoform-specific inhibitors 
established that p110α inhibitors were the most potent at inhibiting IgE plus Ag-induced 
IL-6 production [data not shown]). We employed three different PI3K inhibitors rather than 
just one because all PI3K inhibitors possess some off-target effects. However, because these 
off-target effects tend to differ from one inhibitor to another (44–46), we felt we could be 
more confident that they were exerting their effects via inhibition of PI3K if they all elicited 
the same biological response. As shown in Fig. 7B, we found that low concentrations of 
these three PI3K inhibitors consistently reduced IgE plus Ag-induced pAkt in SHIP+/+ (left 
panel) and LPS-induced pAkt in SHIP−/− (right panel) BMMCs, but did not consistently 
reduce pAkt levels in IgE plus Ag-stimulated SHIP−/− or LPS-induced SHIP+/+ BMMCs, 
unless we went to higher concentrations of inhibitors (data not shown). We then tested these 
inhibitors on IgE plus Ag-induced and LPS-induced IL-6 production from SHIP+/+ and 
SHIP−/− BMMCs and CTMCs, respectively. Of note, LY, W, and PI3Kα inhibitor-2, at the 
concentrations used, had no deleterious effects on cell viability in these cells (data not 
shown). As shown in the left panel of Fig. 7C, these three inhibitors inhibited IgE plus Ag-
induced IL-6 production from both SHIP+/+ and SHIP−/− BMMCs (and MMCs; data not 
shown), and these findings were consistent with the PI3K pathway being a positive regulator 
of IgE plus Ag-induced cytokine production from MCs. However, looking at their effects on 
LPS-induced cytokine production, none of the inhibitors increased IL-6 production above 
control, LPS-induced levels, and LY significantly reduced them (Fig. 7C, right panel). 
Importantly, we tested LY, W, and PI3Kα inhibitor-2 at various concentrations and for 
various times (from 3 to 24 h) for their effects on cytokine production and found that only 
W, at very high concentrations (above 100 nM, where nontarget effects are observed), 
stimulated IL-6 production significantly above control levels (data not shown). Importantly, 
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significant stimulation above control IL-6 levels with high concentrations of W was not seen 
with LPS-stimulated SHIP−/− BMMCs. Because an increase in IL-6 production with low 
levels of PI3K inhibition would be expected, especially in SHIP−/− BMMCs, if the PI3K 
pathway was negatively regulating LPS-induced IL-6 production, we therefore tentatively 
concluded that SHIP positively regulates LPS-induced cytokine production from MCs 
primarily via an adaptor-mediated pathway.
To confirm this, we made numerous attempts to express WT and phosphatase-dead forms of 
SHIP in SHIP−/− CTMCs. However, although we could express these SHIP constructs in 
Phoenix Ampho 293T producer cell lines, we were unsuccessful in achieving detectable 
expression, using either lipofectamine or retroviral infection, in mature SHIP−/− CTMCs, 
BMMCs, or BM progenitors. While engaged in these studies, Ma et al. (47) reported that 
IL-3–stimulated BMMCs that were deficient in PI3K p85α were far less capable of 
activating Akt than WT BMMCs. We therefore investigated whether Akt was also less 
activated in response to LPS in these p85α−/− BMMCs. As shown in Fig. 8A, this was 
indeed the case. This then allowed us to test whether SHIP was promoting LPS-induced 
cytokine production by lowering PI3K/Akt activation or via its role as an adaptor using a 
genetic approach rather than via small molecule inhibitors, with their associated off-target 
effects. If SHIP was promoting LPS-induced IL-6 production by lowering PI3K/Akt 
activation, we would predict that the p85α−/− CTMCs and BMMCs would secrete more IL-6 
than WT cells. As shown in Fig. 8B, however, this was not the case. In fact, the WT CTMCs 
and BMMCs secreted substantially more IL-6. This is consistent with the PI3K pathway 
being a positive regulator of LPS-induced IL-6 production, but that SHIP’s adaptor 
function(s) overrides its negative enzymatic effects on the PI3K pathway.
Discussion
Although BMMCs have been used extensively as a surrogate for in vivo derived MCs, they 
are phenotypically distinct from either MMCs or CTMCs (48), and we have therefore 
compared, in this work, SHIP’s role in the development and activation of CTMCs, MMCs, 
and BMMCs. For the majority of our studies, CTMCs and MMCs were derived from 
SHIP+/+ and SHIP−/− spleen cells (21), because this resulted in robust, homogeneous 
populations of safranin-positive CTMCs and safranin-negative/alcian blue-positive MMCs. 
However, we also derived pCTMCs from SHIP+/+ and SHIP−/− peritoneal cells, as described 
by Malbec et al. (17), and obtained similar results to those obtained with spleen-derived 
CTMCs, both in degranulation (data not shown) and cytokine production studies. However, 
our degranulation results differed from those of Malbec et al. (17), who found that pCTMCs 
degranulated more robustly than BMMCs and that the absence of SHIP did not increase 
their degranulation. Of note, whereas we found that spleen cells yielded far more CTMCs 
upon in vitro culturing than BM cells, it was the cytokine mixture used during in vitro 
expansion that determined the type of mature MC obtained.
In terms of SHIP’s role in the maturation, proliferation, and survival of the three MC 
subsets, they all matured faster in the absence of SHIP, in keeping with our previous results 
with BMMCs (14), but major differences were observed in proliferation, with the absence of 
SHIP enhancing the proliferation of CTMCs, reducing that of BMMCs and having no effect 
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on MMCs. We also found differences in IgE-induced survival, with IgE prolonging the 
survival of CTMCs and MMCs, but the presence of SHIP making no difference to this 
survival. The presence of SHIP in BMMCs, however, actually promoted their proliferation, 
whereas in its absence the BMMCs simply survived. This difference could be related to the 
far more rapid maturation of the SHIP−/− BMMCs, which could explain their subsequent 
reduced proliferation rate and, perhaps, reduced proliferation potential with IgE. However, 
an important caveat to keep in mind when comparing the proliferation and/or survival of 
SHIP+/+ and SHIP−/− BM cells is that SHIP−/− C57BL/6 mice rapidly become systemically 
inflamed, and this might affect hematopoietic precursor frequencies and cytokine exposure 
in vivo. Whereas we used young mice to try and keep these effects to a minimum, we cannot 
rule out that these in vivo conditions could affect the cell types that grow out in vitro.
Examining SHIP’s role in degranulation, we found that SHIP is a potent negative regulator 
of IgE plus Ag-induced degranulation of CTMCs and MMCs, consistent with our earlier 
studies with BMMCs (18). Importantly, TLR ligands alone did not induce degranulation, in 
keeping with previous reports (25, 26), nor did they enhance IgE plus Ag-induced 
degranulation from any MCs, even those lacking SHIP. This contrasts with one report 
claiming that PGN induces the degranulation of BMMCs (27), but this may be because they 
derived their BMMCs with 10% PWM-stimulated spleen cell-conditioned medium rather 
than IL-3 and/or because they derived their BMMCs from C3H/HeN rather than C57BL/6 
mice.
In contrast to our degranulation results, we found substantial differences in cytokine 
production between CTMCs and MMCs/BMMCs. For example, we found much higher 
TLR-induced cytokine production from WT CTMCs than from WT BMMCs, consistent 
with a recent report showing higher cytokine production from TLR2-stimulated pCTMCs 
than from BMMCs (49). Also, although the responses were weak, we found that WT 
BMMCs produced higher levels of IL-6 in response to LPS and dsRNA than SHIP−/− 
BMMCs, suggesting that SHIP is a positive regulator of TLR stimulation in BMMCs as well 
as in CTMCs (Fig. 3). In contrast, IgE plus Ag stimulated far higher cytokine production 
from SHIP−/− MMCs/BMMCs than SHIP−/− CTMCs, and this low IgE plus Ag-induced 
cytokine production from SHIP−/− CTMCs, relative to SHIP−/− BMMCs, cannot be 
explained by a simple lack of response to IgE plus Ag because SHIP−/− CTMCs degranulate 
in response to this stimulus (Fig. 2A). Consistent with our results using IgE+/− TLR ligands 
(Fig. 4), highly cytokinergic IgE alone, in conjunction with TLR2 or TLR4 stimulation, has 
been reported to increase inflammatory cytokines from BMMCs (50). As well, TLR2 and 
TLR4 agonists have been reported to synergize with IgE plus Ag in triggering cytokine 
secretion from BMMCs (26, 28, 51). In contrast, however, TLR2 activation has also been 
reported to reduce both IgE plus Ag-induced BMMC degranulation and TNF-α production 
(52).
To explore why WT MMCs and BMMCs responded so poorly to TLR stimulation and so 
strongly, in the absence of SHIP, to IgE plus Ag, whereas WT CTMCs responded so 
strongly to TLR ligands and so weakly, in the absence of SHIP, to IgE plus Ag, we first 
compared TLR mRNA levels by RT-PCR. We found the expression pattern was more 
limited in WT MMCs and BMMCs (i.e., TLR1, 2, 4, 6) than in WT CTMCs (TLR1, 2, 4, 6, 
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8, 9) and that this is similar, in general, to that reported previously (25, 32, 53). Interestingly, 
we found that the absence of SHIP resulted in higher expression of TLR1, 2, 3, 7, 8, and 9 in 
CTMCs. One caveat, of course, with RT-PCR studies is that they may not reflect cell 
surface protein levels, and this certainly appeared to be the case for TLR9 because RT-PCR 
studies suggested no TLR9 expression in BMMCs or MMCs, whereas we found that CpG 
significantly increased IgE plus Ag-induced IL-6 and TNF-α production from these MCs 
(Fig. 5). Because of this, we honed in on LPS-stimulated events because RT-PCR studies 
suggested similar TLR4 expression levels and subsequent flow cytometric analyses 
confirmed equal cell surface expression of TLR4 and its co-receptor, CD14, on SHIP+/+ and 
SHIP−/− MCs (Supplemental Fig. 2).
Because our subsequent cell signaling studies suggested that the PI3K pathway was more 
activated in the absence of SHIP when stimulated with either LPS or IgE plus Ag, we 
examined the effects of PI3K inhibition and found that LY, W, and PI3Kα inhibitor-2 
reduced IgE plus Ag-induced IL-6 production from SHIP+/+ and SHIP−/− BMMCs/MMCs, 
consistent with the PI3K pathway being a positive regulator of IgE plus Ag-induced 
cytokine production. However, we found that even though SHIP was a positive regulator of 
LPS-induced IL-6 production, PI3K inhibition by three different PI3K inhibitors did not 
increase the levels of this cytokine. The only exception to this finding was when very high 
levels of W were employed and, even then, elevated IL-6 was only seen with WT CTMCs. 
To avoid the off-target effects of PI3K inhibitors, we also compared WT and PI3K p85α−/− 
BMMCs and CTMCs and obtained results consistent with our small molecule PI3K inhibitor 
results, that is, that SHIP may be acting as a positive regulator via its adaptor function(s). 
Our results are consistent with very nice studies showing that W does not inhibit LPS-
induced IL-6 production from WT BMMCs (54) and that SHIP promotes TLR2- and TLR4-
induced cytokine production from murine macrophages (55). However, in the latter study, 
Keck et al. (55) concluded, based on results obtained with high doses of W, that PI3K 
inhibition increased LPS-induced cytokine production in macrophages. Our results also 
contrast with those of Luyendyk et al. (56), who carried out some very elegant genetic 
studies showing that the PI3K/Akt pathway negatively regulates LPS-induced TNF-α and 
IL-6 production in macrophages. However, other studies in macrophages suggest that PI3K 
plays a positive role during LPS-induced cytokine production. For example, Kuo et al. (57) 
found that transfecting RAW264.7 cells with a class I PI3K p110 dominant-negative mutant 
inhibited LPS-induced TNF-α secretion. Our data with p85α−/− CTMCs suggest that, at 
least in MCs, PI3K appears to be playing a positive role. We cannot say at this time whether 
this is a difference between MCs and macrophages or not. Of note, whereas our data are 
consistent with SHIP acting as a positive regulator of TLR-induced cytokines via its adaptor 
function(s), we cannot rule out that it may still be acting as a positive regulator via its 
enzymatic activity by hydrolyzing another substrate (e.g., inositol tetraphosphate) that 
inhibits TLR agonist-induced cytokine production.
The differences we have observed between CTMCs and MMCs/BMMCs are in keeping 
with several previous studies showing significant differences between these MC subsets, 
including differences in TLR expression (49), in responsiveness to IL-18 (which induces 
BMMCs/MMCs, but not CTMCs to secrete the chemokine, Ccll, to recruit Th2 cells) (58), 
in expression of STAT4 (in CTMCs) and STAT6 (in MMCs/BMMCs) (59) and in TLR-
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induced cytokines and chemokines (higher with CTMCs) (25). Differences have also been 
reported in IgE plus Ag-induced survival, with survival being more pronounced with 
CTMCs (60), and this may explain why IgE is a more potent survival enhancer of CTMCs 
than MMCs (Fig. 1C).
In terms of in vivo significance, our finding that TLR agonists trigger far higher levels of 
inflammatory cytokines from WT CTMCs than from WT MMCs makes sense because 
CTMCs are in sterile sites of the body and should be more vigilant toward microbes than 
MMCs, which are in “dirty” environments. As far as MMCs are concerned, our work, 
coupled with recent studies by Haddon et al. (61) showing that it is the absence of SHIP in 
MCs that is responsible for both the increased IL-6 and TNF-α serum levels and the chronic 
lung inflammation that is characteristic of SHIP−/− mice, suggests that it is the high levels of 
IL-6 and TNF-α specifically produced by IgE ± Ag-induced SHIP−/− MMCs that most 
likely drive this chronic lung inflammation (62–64), by attracting and activating other 
immune cells (27, 65, 66). As well, our finding that TLR stimulation augments IgE plus Ag-
induced TNF-α and IL-6 production from MMCs (Fig. 5) might explain the exacerbation of 
IgE-mediated allergic episodes by infectious agents (26) and suggests that activating SHIP 
specifically in MMCs might be useful for treating chronic inflammatory diseases like 
asthma.
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SHIP negatively regulates MC maturation, but positively regulates IgE-induced BMMC 
survival. SHIP+/+ and SHIP−/− CTMC, MMC, and BMMC cultures were initiated, as 
described in Materials and Methods, and (A) their maturity was assessed by surface 
expression of c-kit and FcεR1α. Cells that were doubly positive were considered mature. (B) 
Proliferation was assessed by counting trypan blue excluding cells. Shown is the absolute 
cell number divided by the starting number of cells at week 0. (A and B) SHIP +/+ MCs = ▲ 
with solid lines; SHIP−/− MCs = △ with dashed lines. (C) SHIP+/+ and SHIP−/− MC subsets 
were incubated in 0.1% BSA medium (SHIP+/+ = ▲; SHIP−/− = △, solid lines) or +5 μg/ml 
SPE-7 IgE (SHIP+/+ = #x025BC;; SHIP−/− = ▽, dashed lines), and viable cells were 
counted. Values are the mean ± SD from two independent experiments in triplicate. 
Significant differences (p < 0.05) are indicated (*).
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IgE plus Ag-induced degranulation of CTMCs, MMCs, and BMMCs is repressed by SHIP. 
(A) SHIP+/+ (black bars) and SHIP−/− (white bars) CTMCs, MMCs, and BMMCs were 
preloaded with 0.1 μg/ml IgE for 18 h at 37°C and exposed to the indicated concentration of 
Ag for 1 h at 37°C, and degranulation was assessed. (B) SHIP+/+ (black bars) and 
SHIP−/−(white bars) CTMCs, MMCs, and BMMCs were treated N/S, or exposed to 100 
ng/ml LPS, 50 μg/ml dsRNA, 0.3 μM CpG, or 10 μg/ml PGN for 1 h, and degranulation was 
assessed. (C and D) MCs were preloaded with IgE, as in (A), and then either N/S or treated 
with TLR ligands [same concentrations as in (B)] plus 2 ng/ml Ag (B) or 0.2 ng/ml Ag (C) 
for 1 h. (E) SHIP+/+ (black bars) and SHIP−/−(white bars) BMMCs, MMCs, and CTMCs 
were treated with 10 μg/ml SPE-7 IgE or 400 ng/ml SCF for 1 h at 37°C, and degranulation 
was assessed. As well, as a positive control, SHIP+/+ (black bars) and SHIP−/−(white bars) 
CTMCs were preloaded with 0.1 μg/ml SPE-7 IgE for 18 h at 37°C and exposed to 20 ng/ml 
DNP-HSA for 1 h at 37°C, and degranulation was assessed. Data shown are the means ±SD 
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from at least two independent experiments carried out in duplicate (A–C) or one experiment 
in triplicate (D) or duplicate (E). Similar results were obtained in at least two independent 
experiments.
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TLR-activated WT CTMCs secrete the highest levels of cytokines. SHIP+/+ (black bars) and 
SHIP−/− (white bars) CTMCs, MMCs, and BMMCs were incubated for 24 h with buffer 
alone (N/S), 100 ng/ml LPS, 50 μg/ml dsRNA, or 0.3 μM CpG, and cell-free supernatants 
were assessed for IL-6, TNF-α, IL-12, and IL-10 levels by ELISA. Values shown are the 
mean ± SD from one representative experiment, measured in duplicate. Similar results were 
obtained in three independent experiments.
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IgE synergizes with TLR ligands to trigger TNF-α and IL-6 production from SHIP−/− 
MMCs and BMMCs, but not from CTMCs. SHIP+/+ (black bars) and SHIP−/− (white bars) 
CTMCs, MMCs, and BMMCs were treated for 24 h with 0.1 μg/ml SPE-7 IgE alone (N/S) 
or plus 100 ng/ml LPS, plus 50 μg/ml dsRNA, or plus 0.3 μM CpG, and cell-free 
supernatants were assessed for IL-6, TNF-α, IL-12, and IL-10 levels by ELISA. Values 
shown are the mean ± SD from one representative experiment, measured in duplicate. 
Similar results were obtained in two independent experiments.
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IgE plus Ag dramatically synergizes with TLR ligands to trigger TNF-α and IL-6 production 
from SHIP−/− MMCs and BMMCs, but not from WT or SHIP−/− CTMCs. SHIP+/+ (black 
bars) and SHIP−/− (white bars) CTMCs, MMCs, and BMMCs were treated for 24 h with 0.1 
μg/ml SPE-7 IgE plus 1 ng/ml Ag alone (N/S) or plus 100 ng/ml LPS, plus 50 μg/ml 
dsRNA, or plus 0.3 μM CpG, and cell-free supernatants were assessed for IL-6, TNF-α, 
IL-12, and IL-10 levels by ELISA. Values shown are the means ± SD from one 
representative experiment, measured in duplicate. Similar results were obtained in three 
independent experiments.
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(A) WT peritoneal cell-derived CTMCs also secrete substantially more IL-6 and TNF-α 
than SHIP−/− cells in response to LPS. SHIP+/+ (black bars) and SHIP−/− (white bars) 
BMMCs and MMCs were stimulated with 0.1 μg/ml SPE-7 for 18 h at 37°C, washed, and 
resuspended in MC starvation medium (N/S) ± 2 ng/ml DNP-HSA. SHIP+/+ (black bars) and 
SHIP−/− (white bars) pCTMCs were stimulated ± 100 ng/ml LPS for 24 h at 37°C. Cell-free 
supernatants were assessed for IL-6 (left panel) and TNF-α (right panel) levels by ELISA. 
Values shown are the mean ± SD from one representative experiment, measured in 
duplicate. Similar results were obtained in three independent experiments. (B) TLR 
expression of SHIP+/+ and SHIP−/− CTMCs, MMCs, and BMMCs. For CTMCs, 200 ng 
cDNA was used for RT-PCR, whereas for MMCs and BMMCs 160 ng cDNA was used. As 
a loading control, 100 ng cDNA was used as template in a PCR with primers specific for 
GAPDH. Genomic DNA (10 ng) was used as a positive control. (C) SHIP+/+ (black bars) 
and SHIP−/− (white bars) CTMCs were incubated for 24 h with buffer alone (N/S) or with 
10 μg/ml PGN, and cell-free supernatants were assessed for IL-6, TNF-α, IL-12, and IL-10 
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levels by ELISA. Values shown are the mean ± SD from one representative experiment, 
measured in duplicate. Similar results were obtained in three independent experiments.
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SHIP positively regulates cytokine production from LPS-stimulated MCs via an adaptor 
pathway. (A) SHIP+/+ and SHIP−/− BMMCs were stimulated with IgE plus Ag or LPS for 
the indicated times, and SDS-lysed total cell lysates were subjected to Western analysis, as 
indicated. Short and long refer to exposure times of the x-ray film. (B) SHIP+/+ and SHIP−/− 
BMMCs were pretreated for 30 min with or without the indicated concentration of LY, W, 
or PI3Kα inhibitor-2, and then stimulated with IgE plus Ag (left panel) or LPS (right panel), 
and SDS-lysed total cell lysates were subjected to Western analysis, as indicated. The 
numbers under the IgE plus Ag- and LPS-induced pAkt blots in (B) refer to the levels of 
pAkt, relative to Grb2 (the loading control), determined via densitometry. Similar results 
were obtained in two other experiments. (C) SHIP+/+ (black bars) and SHIP−/− (white bars) 
BMMCs were stimulated with IgE plus Ag (left panel), or SHIP+/+ and SHIP−/− pCTMCs 
were stimulated with LPS (right panel) for 24 h with the indicated concentrations of LY, W, 
or PI3Kα inhibitor-2, and cell-free supernatants were assessed for IL-6 levels by ELISA. 
Values shown are the means ± SD from one representative experiment, measured in 
duplicate. *p < 0.05 compared with no inhibitor. Similar results were obtained in three 
independent experiments for (A and B) and five independent experiments for (C).
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PI3K p85α−/− BMMCs and CTMCs secrete less IL-6 than their WT counterparts. (A) 
BMMCs from WT or p85α−/− mice were starved overnight in serum- and cytokine-free 
media and stimulated with IL-3 (10 ng/ml) or LPS (10 ng/ml) for 15 and 30 min. Equal 
amounts of protein lysates were subjected to Western blot analysis using an anti–phospho-
Akt or total Akt Ab. Similar results were obtained in two independent experiments. (B) 
p85α+/+ (black bars) and p85α−/− (white bars) CT-like BMMCs and CTMCs were 
stimulated with or without 100 ng/ml LPS for 24 h (left panel), or p85α+/+ (black bars) and 
p85α−/− (white bars) BMMCs were stimulated with or without 100 ng/ml LPS or 5 μg/ml 
IgE (as a positive control) for 24 h (right panel), and cell-free supernatants were assessed for 
IL-6 levels by ELISA. Values shown are the means ± SD from one representative 
experiment, measured in duplicate. Similar results were obtained in two independent 
experiments with CT-like BMMCs, two with CTMCs and four with BMMCs.
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